REFRACTORY OSTEOSARCOMA

This early-stage trial tests a personalized cell therapy called GD2CART for children and young adults with neuroblastoma or osteosarcoma that has returned or not responded to standard treatments. The therapy uses the patient's own immune cells (T cells), which are modified in a l…

This study tests whether adding hydroxychloroquine (a drug used for malaria) to standard chemotherapy can help control osteosarcoma that has returned or stopped responding to treatment. About 31 participants will receive the combination to find the safest dose and see if it slows…

This study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…

This study tests a treatment made from a patient's own immune cells (called LN-145) for cancers like ovarian, triple-negative breast, anaplastic thyroid, and bone sarcomas that have not responded to standard therapy or have returned. The cells are taken from the tumor, grown in a…

This study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…

This study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…

This study tests whether two immunotherapy drugs, oleclumab and durvalumab, can shrink or slow the growth of certain sarcomas (angiosarcoma, liposarcoma, and osteosarcoma) that have come back, spread, or stopped responding to standard treatment. About 75 adults and some teens (ag…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…

This study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…